Neuren Pharmaceuticals Limited has released a press release.
DAYBU recommended for approval in the European Union
Earlier from Neuren Pharmaceuticals
- Q1 2026 DAYBUE net sales US$101m, up 20% from Q1 2025
- DAYBUE STIX now broadly available in US for Rett syndrome
- Acadia confirms plan to request CHMP re-examination
- 2025 royalty income A$65m, profit after tax A$30m